research use only

Atenolol Adrenergic Receptor antagonist

Name: Atenolol
Brand: Selleck Chemicals
SKU: S4817
Rating: 5 (4 reviews)

Cat.No.S4817

Atenolol (Tenormin, Normiten, Blokium) is a selective β1 receptor antagonist with log Kd values of −6.66±0.05, −5.99±0.14, −4.11±0.07 for binding to the human β1-, β2- and β3-adrenoceptors.

Chemical Structure

Molecular Weight: 266.34

Jump to

Quality Control

Batch: S481701 DMSO]53 mg/mL]false]Ethanol]53 mg/mL]false]Water]35 mg/mL]false Purity: 99.88%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS
Datasheet

99.88

Related Targets	AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Adrenergic Receptor Inhibitors	ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Naftopidil Detomidine HCl Higenamine hydrochloride Adrenalone HCl Medetomidine HCl Deoxycorticosterone acetate

Chemical Information, Storage & Stability

Molecular Weight	266.34	Formula	C₁₄H₂₂N₂O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	29122-68-7	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Tenormin, Normiten, Blokium			Smiles	CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O

Solubility

In vitro
Batch:

DMSO : 53 mg/mL (198.99 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 53 mg/mL

Water : 35 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.65mg/ml (9.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 53 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.265mg/ml (0.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 5.3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	β1 receptor (Cell-free assay) 0.25 μM(Kd) β2 receptor (Cell-free assay) 1 μM(Kd)
In vivo	In clinical pharmacokinetics studies, Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the Atenolol is metabolised by the liver. After oral administration Atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally bioavailable. In plasma only 3% of Atenolol are protein-bound. After oral administration elimination half life of Atenolol is calculated from 6 to 9 h. There exists a linear relationship between the Atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia while no correlation is found between plasma levels of Atenolol and blood pressure lowering activity of the drug.
References	[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1576008/ [2] https://pubmed.ncbi.nlm.nih.gov/6142665/ [3] https://pubmed.ncbi.nlm.nih.gov/6749509/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04224675	Unknown status	Aneurysm	Onassis Cardiac Surgery Centre	March 7 2020	Not Applicable
NCT01719367	Completed	Atrial Fibrillation	Vanderbilt University Medical Center	January 2013	Not Applicable
NCT01361087	Withdrawn	Marfan Syndrome	Ann & Robert H Lurie Children''s Hospital of Chicago\|Johns Hopkins University	April 2011	Phase 3
NCT01132768	Terminated	Essential Hypertension\|Carotid Plaque	Daiichi Sankyo Europe GmbH a Daiichi Sankyo Company\|Daiichi Sankyo	May 2010	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):